Method of treating cancer using combination of a bifunctional alkylating agent and DNA repair inhibitors
A pharmaceutical composition for treating cancer, in particular drug resistant cancer, comprising an effective amount of bifunctional alkylating agent, an effective amount of a DNA repair inhibitor, and a pharmaceutically acceptable carrier.
1. A pharmaceutical composition for treating cancer comprising an effective amount of a derivative of 3a-aza-cyclopentaindene selected from the group consisting of BO-1012, an effective amount of a DNA repair inhibitor, and a pharmaceutically acceptable carrier.
2. The composition of claim 1 wherein the DNA repair inhibitor is selected from the group consisting of arsenic trioxide, LY294002, and triciribine.
3. A method of treating cancer suffered by a mammalian subject comprising administering to the subject an effective amount of BO-1012 and an effective amount of a DNA repair inhibitor.
4. The method of claim 3 wherein the subject is administered with the BO-1012 before being administered with the DNA repair inhibitor.
5. The method of claim 3 wherein the DNA repair inhibitor is selected from the group consisting of ATO, Ly294002, and triciribine.
6. The method of claim 3 wherein the cancer is resistant to an individual therapeutic agent.
7. The method of claim 3 wherein the cancer is human lung cancer.
8. The method of claim 3 wherein the cancer is human bladder cancer.
9. The method of claim 3 wherein the cancer is human breast cancer.
10. The method of claim 3 wherein the cancer is human prostate cancer.
11. The method of claim 3 wherein the cancer is human glioma cancer.
12. The method of claim 3 wherein the cancer is human oral cancer.
13. A pharmaceutical composition for treating cancer comprising an effective amount of BO-1509, an effective amount of a DNA repair inhibitor, and a pharmaceutically acceptable carrier.
14. The composition of claim 13 wherein the DNA repair inhibitor is selected from the group consisting of arsenic trioxide, LY294002, and triciribine.